161 related articles for article (PubMed ID: 34634130)
1. Risk of corticosteroid treatment and hospitalization after checkpoint inhibitor and radiation therapy in patients with cancer.
Lee KE; Bender DA; Koutcher LD; Hyde B; Hur C; Faye AS; Cheng SK
Cancer; 2022 Feb; 128(4):819-827. PubMed ID: 34634130
[TBL] [Abstract][Full Text] [Related]
2. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
3. Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer.
Kehl KL; Yang S; Awad MM; Palmer N; Kohane IS; Schrag D
Cancer Immunol Immunother; 2019 Jun; 68(6):917-926. PubMed ID: 30877325
[TBL] [Abstract][Full Text] [Related]
4. Increased rates of immunosuppressive treatment and hospitalization after checkpoint inhibitor therapy in cancer patients with autoimmune disease.
Bender DA; Heilbroner SP; Wang TJC; Shu CA; Hyde B; Spina C; Cheng SK
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33303578
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer.
Chitturi KR; Xu J; Araujo-Gutierrez R; Bhimaraj A; Guha A; Hussain I; Kassi M; Bernicker EH; Trachtenberg BH
JACC CardioOncol; 2019 Dec; 1(2):182-192. PubMed ID: 34396181
[TBL] [Abstract][Full Text] [Related]
6. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
7. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
Li M; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
Cancer; 2020 Dec; 126(23):5088-5097. PubMed ID: 32888341
[TBL] [Abstract][Full Text] [Related]
8. High-dose corticosteroid use and risk of hospitalization for infection in patients treated with immune checkpoint inhibitors--A nationwide register-based cohort study.
Sørup S; Darvalics B; Russo L; Oksen D; Lamy FX; Verpillat P; Aa K; Ht S; Cronin-Fenton D
Cancer Med; 2021 Jul; 10(14):4957-4963. PubMed ID: 34105315
[TBL] [Abstract][Full Text] [Related]
9. The clinical value of combination of immune checkpoint inhibitors in cancer patients: A meta-analysis of efficacy and safety.
Wu Y; Shi H; Jiang M; Qiu M; Jia K; Cao T; Shang Y; Shi L; Jiang K; Wu H
Int J Cancer; 2017 Dec; 141(12):2562-2570. PubMed ID: 28833119
[TBL] [Abstract][Full Text] [Related]
10. Association of Radiation Therapy With Risk of Adverse Events in Patients Receiving Immunotherapy: A Pooled Analysis of Trials in the US Food and Drug Administration Database.
Anscher MS; Arora S; Weinstock C; Amatya A; Bandaru P; Tang C; Girvin AT; Fiero MH; Tang S; Lubitz R; Amiri-Kordestani L; Theoret MR; Pazdur R; Beaver JA
JAMA Oncol; 2022 Feb; 8(2):232-240. PubMed ID: 34989781
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitor with or without Radiotherapy in Melanoma Patients with Brain Metastases: A Systematic Review and Meta-Analysis.
Kim PH; Suh CH; Kim HS; Kim KW; Kim DY; Lee EQ; Aizer AA; Guenette JP; Huang RY
Korean J Radiol; 2021 Apr; 22(4):584-595. PubMed ID: 33289357
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
13. Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung Cancer.
Hubbeling HG; Schapira EF; Horick NK; Goodwin KEH; Lin JJ; Oh KS; Shaw AT; Mehan WA; Shih HA; Gainor JF
J Thorac Oncol; 2018 Apr; 13(4):550-558. PubMed ID: 29378267
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy to Control Limited Melanoma Progression Following Ipilimumab.
Kropp LM; De Los Santos JF; McKee SB; Conry RM
J Immunother; 2016; 39(9):373-378. PubMed ID: 27662339
[TBL] [Abstract][Full Text] [Related]
15. Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors.
Tyan K; Baginska J; Brainard M; Giobbie-Hurder A; Severgnini M; Manos M; Haq R; Buchbinder EI; Ott PA; Hodi FS; Rahma OE
Cancer Immunol Immunother; 2021 Aug; 70(8):2209-2221. PubMed ID: 33481042
[TBL] [Abstract][Full Text] [Related]
16. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
[TBL] [Abstract][Full Text] [Related]
17. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
[TBL] [Abstract][Full Text] [Related]
18. Impact of previous corticosteroid exposure on outcomes of patients receiving immune checkpoint inhibitors for advanced non-small cell lung cancer: a retrospective observational study.
Nelli F; Virtuoso A; Berrios JRG; Giannarelli D; Fabbri A; Marrucci E; Ruggeri EM
Cancer Chemother Pharmacol; 2022 Apr; 89(4):529-537. PubMed ID: 35301584
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation.
Chanson N; Ramos-Casals M; Pundole X; Suijkerbuijk K; José de Barros E Silva M; Lidar M; Benesova K; Leipe J; Acar-Denizli N; Pradère P; Michot JM; Voisin AL; Suárez-Almazor ME; Radstake TRD; Fernandes Moça Trevisani V; Schulze-Koops H; Melin A; Robert C; Mariette X; Baughman RP; Lambotte O; ; ; ; ; ;
Eur J Cancer; 2021 Nov; 158():208-216. PubMed ID: 34452793
[TBL] [Abstract][Full Text] [Related]
20. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry.
Sun MM; Kelly SP; Mylavarapu Bs AL; Holland GN; Coleman AL; Yu F; Hsu Ms S; Lum F; Gordon LK
Ophthalmology; 2021 Jun; 128(6):910-919. PubMed ID: 33166553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]